VIVS on Nasdaq

VivoSim Labs, INC.

American biological products company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

$131.0KRevenue, fiscal 20262
-$13.8MNet income, fiscal 20262

Compare with Candel Therapeutics, Instil Bio, Inc. or Zivo Bioscience, Inc., or pick any stock.

  • TickerVIVS on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego, California1
  • Incorporated inDE3
  • Business address11555 Sorrento Valley Road, Suite 100, San Diego, Ca 921213
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies ("NAM") models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-8768.7%Operating margin2
-10567.2%Net margin2
-9.0%Revenue growth, 20262
-$10.8MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Research and development36¢$4.2M
  • Selling, general and admin64¢$7.4M
  • Income tax0¢$2.0K

Out of $131.0K in revenue.2 The company lost money this year.

Financial statements

Revenue56789102$131.0K in 2026−96% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $3.1M$3.1M20192020: $2.2M$2.2M2020−29%2021: $0$020212022: $1.5M$1.5M20222023: $370.0K$370.0K2023−75%2024: $109.0K$109.0K2024−71%2025: $144.0K$144.0K2025+32%2026: $131.0K$131.0K2026−9%
Operating income56789102-$11.5M in 2026−58% since 2019
-$30.0M-$20.0M-$10.0M02019: -$27.3M-$27.3M20192020: -$21.5M-$21.5M2020−21%2021: -$16.8M-$16.8M2021−22%2022: -$11.5M-$11.5M2022−32%2023: -$17.7M-$17.7M2023+54%2024: -$15.1M-$15.1M2024−15%2025: -$12.6M-$12.6M2025−16%2026: -$11.5M-$11.5M2026−9%
Net income56789102-$13.8M in 2026−48% since 2019
-$30.0M-$20.0M-$10.0M02019: -$26.6M-$26.6M20192020: -$18.7M-$18.7M2020−30%2021: -$16.8M-$16.8M2021−10%2022: -$11.4M-$11.4M2022−32%2023: -$17.3M-$17.3M2023+51%2024: -$14.7M-$14.7M2024−15%2025: -$2.5M-$2.5M2025−83%2026: -$13.8M-$13.8M2026+456%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-03-312025-03-31
Total Revenues$131.0K$144.0K
Cost of revenues$0$5.0K
Research and development expenses$4.2M$5.0M
Selling, general, and administrative expenses$7.4M$7.7M
Total costs and expenses$11.6M$12.8M
Loss from Operations-$11.5M-$12.6M
Loss on issuance of common stock-$2.7M$0
Gain on investment in equity securities$94.0K$0
Gain on sale of asset$0$10.0M
Interest income$267.0K$140.0K
Interest expense-$12.0K-$10.0K
Total Other Income (Expense)-$2.4M$10.1M
Income Tax Expense-$2.0K-$2.0K
Net Loss-$13.8M-$2.5M
Comprehensive Loss-$13.8M-$2.5M
Net loss per common share basic-$5.35-$1.70
Net loss per common share diluted-$5.35-$1.70
Weighted average shares used in computing net loss per common share basic2.6M shares1.5M shares
Weighted average shares used in computing net loss per common share diluted2.6M shares1.5M shares

Compare VivoSim Labs, INC. with another company

Leadership

Who has led VivoSim Labs, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Keith Murphy2012–2017
  2. Taylor Crouch2017–2020

Chair

  1. Keith Murphy2012–now

President

  1. Keith Murphy2012–2017
  2. Taylor Crouch2017–2020
  3. Chris Heberlig2020

Chief financial officer

  1. Barry D. Michaels2012–2016
  2. Craig Kussman2016–2020
  3. Chris Heberlig2020
201520202025
Board members and other officers (25)

Former names

  • ORGANOVO HOLDINGS, INC.Jan 4, 2012 to Apr 23, 20253
  • REAL ESTATE RESTORATION & RENTAL, INC.Aug 4, 2010 to Oct 31, 20113

Timeline

  1. Apr 24, 2017New chief executive Taylor Crouch becomes CEO14
  2. Mar 13, 2012New chief executive Keith Murphy becomes CEO15

Filings

186 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 43 major events, 44 insider forms, 12 large holders, 64 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Sep 1, 20264 EDGAR
  3. Aug 21, 2026ARS EDGAR
  4. Aug 21, 20268-K EDGAR
  5. Aug 21, 2026DEF 14A EDGAR
  6. Aug 17, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 2026PRER14A EDGAR
  8. Aug 12, 202610-Q EDGAR
  9. Aug 10, 2026EFFECT EDGAR
  10. Aug 10, 2026PRE 14A EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Jul 31, 2026S-1 EDGAR
  13. Jul 30, 20268-K EDGAR
  14. Jul 24, 20268-K CURRENT REPORT EDGAR
  15. Jul 17, 20268-K EDGAR
  16. Jul 14, 202610-K EDGAR
  17. Jun 29, 2026NT 10-K EDGAR
  18. Apr 6, 2026SCHEDULE 13G EDGAR
  19. Apr 3, 20268-K EDGAR
  20. Apr 2, 2026424B4 PROSPECTUS EDGAR

The 186 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 1 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Lialin Tony SergeChief Commercial OfficerBuy10,000$0.28$2.8KForm 4
Nov 17, 2025Gobel DavidDirectorSale3,266$2.24$7.3KForm 4
Nov 15, 2023Gobel DavidDirectorSale19,607$1.62$31.8KForm 4
Nov 19, 2021Gobel DavidDirectorSale145$5.29$767Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Geode Capital Management, LLC25,976$27.8K0.0%−10,874
Renaissance Technologies LLC18,500$19.8K0.0%New
Vanguard Capital Management LLC15,371$16.4K0.0%No change
BlackRock, Inc.11,817$12.6K0.0%No change
Vanguard Fiduciary Trust Co7,003$7.5K0.0%No change
Tower Research Capital LLC (TRC)5,249$5.6K0.0%+2,941
SBI Securities Co., Ltd.221$2360.0%No change
Larson Financial Group LLC166$1780.0%No change
Albion Financial Group /ut159$1710.0%No change
Wells Fargo & Company/mn111$1190.0%No change
Osaic Holdings, Inc.84$880.0%−11
Morgan Stanley49$520.0%−1
UBS Group AG18$200.0%−934
Hrt Financial LP18,319$190.0%New
Caitong International Asset Management Co., Ltd17$180.0%+14
IFG Advisory, LLC14$150.0%New
Integrated Wealth Concepts LLC8$90.0%New
Rockefeller Capital Management L.P.2$20.0%No change
Golden State Wealth Management, LLC2$20.0%No change
Activest Wealth Management2$20.0%No change
Federation des caisses Desjardins du Quebec2$20.0%No change
Harbour Investments, Inc.1$10.0%No change
First Command Advisory Services, Inc.1$10.0%No change
Hilton Head Capital Partners, LLC1$10.0%No change
Royal Bank Of Canada1$00.0%−1

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47